Molecular MedicineMetabolic engineering and diabetes therapy
The group directed by Prof. Guinovart is involved in several projects on glycogen metabolism and its dysfunctions in diabetes and Lafora disease. Studies on glycogen metabolism have allowed the identification of many enzymes and intermediate metabolites involved in the synthesis and degradation of this polysaccharide. However, new factors and processes that participate in glycogen regulation are constantly being discovered. Moreover, data on the mechanisms of control in distinct organs and in diverse physiological conditions are incomplete. The alteration of one of these mechanisms may lead to serious pathologies such as diabetes mellitus and Lafora disease. The discovery of compounds that counteract the alterations of glucose metabolism is of potential interest for the treatment of diabetes mellitus.
- To study the mechanisms of glucose storage in the form of glycogen in liver, muscle and brain and its alterations in diabetes and neurological disorders.
- To identify and characterize novel compounds with anti-diabetic action.
- To identify novel potential molecular targets for the design of anti-diabetic compounds.
1) To characterise the physiological role of glycogen in the CNS and in particular in neurons.
a) To study the molecular changes associated with the lack of glycogen in the brain.
b) To further demonstrate the presence of glycogen in neurons and analyse its role in the normal functioning of this cell type.
2) To study the pathological consequences of neuronal glycogen accumulation in pathological conditions and aging.
a) To further examine the molecular mechanism(s) of neurodegeneration induced by the accumulation of glycogen.
b) To address the reversibility of abnormal glycogen accumulation in Lafora disease.
c) To study the role of neuronal glycogen accumulation in the etiopathogeny of ALS, diabetic complications, and aging.
3) To analyse the consequences of abnormal accumulation of glycogen in muscular glycogenoses.
a) To study the consequences of the over-accumulation of glycogen in skeletal muscle.
b) To examine the contribution of glycogen accumulation in neurons to the physiopathology of Pompe disease.
4) To analyse the role of hepatic glycogen in feeding behaviour.
a) To study how the amount of liver glycogen regulates food intake.
b) To determine hepatic ATP involvement in food intake.
5) To revisit the role of glycogenin in glycogen synthesis.
a) To characterise an animal model lacking glycogenin (GYG).
b) To study other possible functions of GYG besides glycogen initiation.
* shared senior authorship
This group receives financial support from the following sources:
- Instituto de Salud Carlos III. Ministerio de Sanidad y Consumo (Spanish National Institute of Health)
- Fundació “La Caixa” ("la Caixa" Foundation)
- Ministerio de Educación y Ciencia (Spanish Ministry of Education and Science)
- Fundación Marcelino Botín (M. Botín Foundation)
- Marató de TV3
- Ministerio de Economía y Competitividad (MINECO)
- European Commission (EC), Fondo Europeo de Desarrollo Regional (FEDER), "Una manera de hacer Europa"
Group news & mentions
La Marató awards funding to two IRB Barcelona projects on obesity and diabetes
An international consortium to study a fatal form of epilepsy
The United States brings together five labs worldwide to study a fatal form of epilepsy
Joan Guinovart named Doctor Honoris Causa by the Andrés Bello National University of Chile
Group news & mentions
Today the Fundació La Marató de TV3 has announced the 34 winning projects out of 117 presented for funding in the 2015 campaign devoted to obe
The medical newspaper “Correo Farmacéutico” has echoed a recently launched international consortium that seeks to find a treatment for Lafora disease—the most severe type of epilepsy in humans.
22FebHow can fluorescence help to understand macromolecular interactions in bacterial division and metabolism?
22FebModeling human diseases in C. elegans: Could CRISPR and worms help to improve your health?
23FebMechanisms regulating stem cell properties and immune interplay of tumor-initiating cells